Ask AI
ProCE Banner Activity

ADH1 in Hypoparathyroidism: Detection and CaSR-Targeted Therapies

Slideset

Access this slide set for clues on the pathophysiology, detection, and evolving treatment of ADH1, a rare genetic disorder affecting calcium and PTH regulation.

Released: June 11, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with HypoPARAthyroidism Association, Inc.

ProCE Banner

Supporters

This activity is supported by an independent educational grant from BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

Partners

HypoPARAthyroidism Association, Inc

ProCE Banner

Target Audience

This activity is designed for clinicians involved in the management of patients with ADH1, including endocrinologists, nephrologists, primary care physicians, orthopedists, nurse practitioners, physician associates, and other members of the care team. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify ADH1 as an underrecognized cause of hypoparathyroidism by recognizing clinical features that raise suspicion for the diagnosis

  • Understand the activating mutations in the calcium-sensing receptor (CaSR) gene that underlie ADH1

  • Apply genetic testing strategies for suspected ADH1, including appropriate test selection, result interpretation, and consideration of access and ethical implications, to confirm diagnosis and inform clinical management

  • Evaluate emerging clinical trial evidence for novel therapeutic approaches that target the underlying causes of ADH1, including CaSR-targeted therapies, to optimize calcium homeostasis and reduce renal complications